[ljpc.jpg]

February 3, 2015

Lakhmir Chawla, MD

RE: Offer of Employment

La Jolla Pharmaceutical Company (the “Company”) is pleased to offer you the
full-time position of Chief Medical Officer. Your anticipated starting date of
full-time employment (“Employment Start Date”) will be tentatively July 1, 2015;
during the interim period, it is expected that you will continue to serve as a
consultant to the Company on separate terms previously established. This offer
and your employment relationship will be subject to the terms and conditions of
this letter.

You will be expected to devote your full business time and your best
professional efforts, judgment, knowledge and skill exclusively to the
performance of your duties and responsibilities for the Company and its
affiliates, and to abide by all Company policies and codes of conduct, as in
effect from time to time. You will report to the Chief Executive Offer and be
expected to perform the duties of your position and such other duties as may be
assigned to you from time to time.

If you decide to join us, your initial annual base salary will be $380,000, less
applicable withholdings and deductions, paid in accordance with the Company’s
normal payroll practices (“Base Salary”). Thereafter, the Company’s Board of
Directors will consider you for annual increases in base salary in accordance
with Company policy and subject to review and approval. Additionally, you will
be eligible for an annual bonus, in a target amount equal to 35% of your annual
base salary, subject to achievement of individual and Company goals established
annually (the “Target Bonus”). Annual bonus payouts will be pro-rated for your
first year of service and payment will be conditioned upon your continued
employment with the Company through the date of payment; you will not be
eligible to bonus payments for completed fiscal years if your service terminates
prior to the date of payment.

The Company recognizes the importance of you maintaining your clinical skills as
a physician. Accordingly, the Company will support you in conducting clinical
work, and you will be permitted to practice medicine in the fields of internal
medicine, critical care and/or nephrology for up to 8 weeks annually, provided
that such activities shall not substantively interfere with your ability to
perform your duties as an officer and employee of the Company. The 8-week time
period will be separate and independent from your personal or any other leave
you may receive as part of your benefits package.
Upon your commencement of full-time employment, the Company agrees to reimburse
you up to $22,500 for the cost of moving expenses related to your relocation to
California. In addition, the Company will provide up to six months of rental
reimbursement to assist with your relocation at a total amount not to exceed
$[5,000] monthly.

--------------------------------------------------------------------------------

[ljpc.jpg]

Please understand that your offer of employment is contingent upon the
satisfactory outcome of a personal background check, which, depending upon your
position and department, may include professional references, verification of
previous employment and education, criminal background check, drug screening, a
department motor vehicle (DMV) check and/or a consumer credit check.

As an employee of the Company, you will eligible to continue vesting that
certain stock award previously granted by the Company representing the right to
purchase up to 60,000 shares of Company common stock (the “Option”).
Accordingly, the Option will continue to vest during your employment, subject to
your continued service during this time.

During your employment, you will be eligible to participate in any and all
employee benefit plans made available by the Company from time to time to its
employees generally, subject to plan terms and generally applicable Company
policies. In addition to holidays observed by the Company, you will be eligible
for vacation in accordance with the policies of the Company, as in effect from
time to time. The Company reserves the right to change or eliminate its benefits
on a prospective basis at any time

If you accept our offer, your employment with the Company will be “at-will.”
This means your employment is not for any specific period of time and can be
terminated by you at any time for any reason. Likewise, the Company may
terminate the employment relationship at any time, with or without cause or
advance notice. In addition, the Company reserves the right to modify your
position, duties or reporting relationship to meet business needs, and to use
its managerial discretion in deciding on appropriate discipline when it deems
circumstances so warrant.

If, within two years from the Employment Start Date, your employment is
terminated by the Company without “Cause,” or by you for “Good Reason,” then you
shall be entitled to receive the “Severance Payments” (defined below), subject
to your execution and delivery of a fully effective and irrevocable Release and
Waiver in the form attached hereto as Exhibit A (which shall be delivered within
45 days following termination of your employment). For purposes of this
agreement, the Severance Payments shall mean the sum of: (i) a series of
payments over a six-month period (payable on the Company’s normal payroll dates)
equal in the aggregate to the sum of: (A) six months of the Base Salary then in
effect, and (B) one-half of the then-applicable Target Bonus, in each case less
required deductions and withholdings; (ii) accelerated time-based vesting of
shares subject to all stock awards issued by the Company, for the number of
shares which would have vested accordingly had you continued employment with the
Company for a period of six months after termination; and (iii) to the extent
permissible under applicable law, reimbursement for or continuation of payment
by the Company of its portion of the health insurance benefits provided to you
immediately prior to termination pursuant to the terms of the Consolidated
Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) or other
applicable law for a period of up to 6 months from the date of termination.

If, within two years from the Employment Start Date, your employment is
terminated by the Company without Cause, or by you for Good Reason, and such
termination occurs within 12 months following a Change in Control, then you
shall instead be entitled to receive the “Change

--------------------------------------------------------------------------------

[ljpc.jpg]

of Control Severance Payments” (defined below), subject to your execution and
delivery of a fully effective and irrevocable Release and Waiver in the form
attached hereto as Exhibit A (which shall be delivered within 45 days following
termination of your employment). For purposes of this agreement, the Change of
Control Severance Payments shall mean the sum of: (i) a lump sum payment equal
to 100% of the Base Salary then in effect, less required deductions and
withholdings; (ii) the greater of your Target Bonus then in effect, less
required deductions and withholdings, or the amount of the actual bonus payout
paid in the year preceding the year in which termination occurs, less required
deductions and withholdings; (iii) full accelerated time-based vesting of shares
subject to all stock awards issued to you by the Company; and (iv) to the extent
permissible under applicable law and provided that you timely elect continued
coverage under COBRA, the COBRA benefit for a period of up to 12 months. For the
avoidance of doubt, in the event of a Change of Control, you shall be eligible
to receive either the Severance Payments or the Change of Control Severance
Payments, but not both, and in each case, subject to the conditions set forth
herein.

For purposes of this agreement, “Cause” means that, in the reasonable
determination of the Company, you have:
(i)
been indicted for or convicted of or pleaded guilty or no contest to any felony
or crime involving dishonesty that is likely to inflict or has inflicted
demonstrable and material injury on the business of the Company;

(ii)
participated in any fraud against the Company;

(iii)
willfully and materially breached a Company policy;

(iv)
intentionally damaged any property of the Company thereby causing demonstrable
and material injury to the business of the Company; or

(v)
engaged in conduct that, in the reasonable determination of the Company,
demonstrates gross unfitness to serve.

For purposes of this Agreement, “Change in Control” means the occurrence of any
of the following: the consummation of an Ownership Change Event or a series of
related Ownership Change Events (collectively, a “Transaction”) in which the
stockholders of the Company immediately before the Transaction do not retain
immediately after the Transaction, in substantially the same proportions as
their ownership of shares of the Company’s voting stock immediately before the
Transaction, direct or indirect beneficial ownership of more than fifty percent
(50%) of the total combined voting power of the outstanding voting securities of
the Company or such surviving entity immediately outstanding after the
Transaction, or, in the case of an applicable Ownership Change Event the entity
to which the assets of the Company were transferred (the “Transferee”), as the
case may be. For purposes of the preceding sentence, indirect beneficial
ownership shall include, without limitation, an interest resulting from
ownership of the voting securities of one or more corporations or other business
entities which own the Company or the Transferee, as the case may be, either
directly or through one or more subsidiary corporations or other business
entities. The Board shall have the right to determine

--------------------------------------------------------------------------------

[ljpc.jpg]

whether multiple sales or exchanges of the voting securities in the Company
or multiple Ownership Change Events are related, and its determination shall be
final, binding and conclusive. “Ownership Change Event” means the consummation
of any of the following with respect to the Company: (i) the direct or indirect
sale or exchange in a single or series of related transactions by the
stockholders of the Company of more than 50% of the voting stock of the Company;
(ii) a merger or consolidation in which the Company is a party; or (iii) the
sale, exchange, or transfer of all or substantially all of the assets of the
Company.
For purposes of this agreement, “Good Reason” shall mean the occurrence of any
of the following events without your consent:
(i)
a material reduction (which shall mean 20% or more) by the Company of the Base
Salary as initially set forth herein or as the same may be increased from time
to time;

(ii)
a material reduction by the Company of your management responsibilities;

(iii)
a material breach of this Agreement by the Company;

provided however, that your resignation due to any of the foregoing conditions
shall only be deemed for Good Reason if: (i) you give the Company written notice
of the intent to terminate for Good Reason within 90 days following the first
occurrence of the condition(s) that you believe constitutes Good Reason, which
notice shall describe such condition(s); (ii) the Company fails to remedy, if
remediable, such condition(s) within 30 days following receipt of the written
notice (the “Cure Period”) of such condition(s) from you; and (iii) you actually
resign your employment within the first 30 days after expiration of the Cure
Period.
Notwithstanding anything to the contrary set forth herein, any payments and
benefits provided under this Agreement that constitute the payment of “deferred
compensation” within the meaning of Section 409A of the Internal Revenue Code of
1986, as amended (the “Code”) and the regulations and other guidance thereunder
and any state law of similar effect (collectively “Section 409A”) that are
payable upon termination of employment shall not commence in connection with
your termination of employment unless and until you have also incurred a
“separation from service” (as such term is defined in Treasury Regulation
Section 1.409A-1(h) (“Separation From Service”)).

It is intended that each installment payment provided for in this Agreement is a
separate “payment” for purposes of Treasury Regulation Section
1.409A-2(b)(2)(i). For the avoidance of doubt, it is intended that payments of
the severance benefits set forth herein (consisting of either the Severance
Payments or the Change of Control Severance Payments, and collectively referred
to as the “Severance Benefits”) satisfy, to the greatest extent possible, the
exemptions from the application of Section 409A provided under Treasury
Regulation Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9). However,
if the Company (or, if applicable, the successor entity thereto) determines that
the Severance Benefits constitute “deferred compensation” under Section 409A
that is not exempt from Section 409A and you are, at the time of your Separation
From Service, a “specified employee” of the Company or any successor entity
thereto, as such term is defined in Section 409A(a)(2)(B)(i) of the Code, then,
solely to the extent necessary to

--------------------------------------------------------------------------------

[ljpc.jpg]

avoid the incurrence of the adverse personal tax consequences under Section
409A, the timing of the Severance Benefit payments shall be delayed until the
earlier to occur of: (i) the date that is six months and one day after your
Separation From Service or (ii) the date of your death (such applicable date,
the “Specified Employee Initial Payment Date”), and the Company (or the
successor entity thereto, as applicable) shall (A) pay to you a lump sum amount
equal to the sum of the Severance Benefit payments that you would otherwise have
received through the Specified Employee Initial Payment Date if the commencement
of the payment of the Severance Benefits had not been so delayed pursuant to
this Section and (B) commence paying the balance of the Severance Benefits in
accordance with the applicable payment schedules set forth in this Agreement.
 
Except to the extent that payments may be delayed until the Specified Employee
Initial Payment Date pursuant to the preceding paragraph, on the first regular
payroll pay day following the effective date of the Release and Waiver, the
Company will pay you the Severance Benefits you would otherwise have received
under the Agreement on or prior to such date but for the delay in payment
related to the effectiveness of the Release and Waiver, with the balance of the
Severance Benefits being paid as originally scheduled. All amounts payable under
the Agreement will be subject to standard payroll taxes and deductions.

This offer is contingent upon the following:

•
You signing and abiding by the Company’s Proprietary Information, Nondisclosure,
and Assignment Agreement (see enclosed);

•
You signing the Company’s Mutual Agreement to Arbitrate (see enclosed);

•
Your compliance with federal I-9 requirements (although you have three days to
complete this process, please provide suitable documentation on your first day
of work verifying your identity and legal authorization to work in the United
States).

This letter, including the enclosed Proprietary Information, Nondisclosure, and
Assignment Agreement and Mutual Agreement to Arbitrate, constitutes the entire
agreement between you and the Company relating to this subject matter, and
supersedes all prior or contemporaneous agreements, understandings, negotiations
and representations, whether oral or written, express or implied, on this
subject. This letter may not be modified or amended, and no breach is to be
regarded as waived, unless agreed to in a specific, written agreement signed by
you and the Company. This letter shall be governed and construed in accordance
with the laws of the State of California, without regard to the conflict of laws
principles thereof.

To indicate your acceptance of the Company’s offer, subject to the terms and
conditions set forth in this letter, please sign and date this letter in the
space provided below and return it to our offices at 4660 La Jolla Village
Drive, Suite 1070, San Diego, CA 92122 or by email to srowe@ljpc.com. If you do
accept as provided, this letter will take effect as a binding agreement between
you and the Company on the later of: (a) the date it is received, provided that
you also sign, date and return the Company’s Proprietary Information,
Nondisclosure, and Assignment Agreement and Mutual Agreement to Arbitrate; or
(b) the Employment Start Date. Acceptance of this letter prior to the Employment
Start Date shall not create any binding rights or obligations

--------------------------------------------------------------------------------

[ljpc.jpg]

(with respect to either party) prior to the Employment Start Date, and such
rights and obligations shall be created at that time only if neither party has
delivered written notice of the rejection of this letter agreement prior to that
time (which notice may be delivered at any time prior to the Employment Start
Date and for any reason).

We hope your employment with the Company will prove mutually rewarding, and we
look forward to having you join us. If you have any questions, please feel free
to call me at (858) 256-7910.

Sincerely,

/s/ George F. Tidmarsh, MD, PhD
George F. Tidmarsh, MD, PhD    
Chief Executive Officer

ACCEPTED AND AGREED:

Dated: February 21, 2015     /s/ Lakhmir Chawla, M.D.
Lakhmir Chawla, M.D.

--------------------------------------------------------------------------------

[ljpc.jpg]

EXHIBIT A
RELEASE AND WAIVER OF CLAIMS
TO BE SIGNED AT TIME OF TERMINATION WITHOUT CAUSE OR
RESIGNATION FOR GOOD REASON
In consideration of the severance payments and other post-employment benefits
set forth in that certain employment offer letter, dated _____, to which this
form is attached (the “Employment Agreement”), I, Mink Chawla, M.D. hereby
furnish La Jolla Pharmaceutical Company (the “Company”), with the following
release and waiver (the “Release and Waiver”).
In exchange for the consideration provided to me by the Employment Agreement
that I am not otherwise entitled to receive, I hereby generally and completely
release the Company and its directors, officers, employees, stockholders,
partners, agents, attorneys, predecessors, successors, parent and subsidiary
entities, insurers, Affiliates, and assigns from any and all claims, liabilities
and obligations, both known and unknown, that arise out of or are in any way
related to events, acts, conduct, or omissions occurring prior to my signing
this Release and Waiver. This general release includes, but is not limited to:
(1) all claims arising out of or in any way related to my employment with the
Company or the termination of that employment; (2) all claims related to my
compensation or benefits from the Company, including, but not limited to,
salary, bonuses, commissions, vacation pay, expense reimbursements, severance
pay, fringe benefits, stock, stock options, or any other ownership interests in
the Company; (3) all claims for breach of contract, wrongful termination, and
breach of the implied covenant of good faith and fair dealing; (4) all tort
claims, including, but not limited to, claims for fraud, defamation, emotional
distress, and discharge in violation of public policy; and (5) all federal,
state, and local statutory claims, including, but not limited to, claims for
discrimination, harassment, retaliation, attorneys’ fees, or other claims
arising under the federal Civil Rights Act of 1964 (as amended), the federal
Americans with Disabilities Act of 1990, the federal Age Discrimination in
Employment Act of 1967 (as amended) (“ADEA”), and the California Fair Employment
and Housing Act (as amended).
I also acknowledge that I have read and understand Section 1542 of the
California Civil Code which reads as follows:
“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR
SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH
IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH
THE DEBTOR.”
I hereby expressly waive and relinquish all rights and benefits under that
section and any law of any jurisdiction of similar effect with respect to any
claims I may have against the Company.

--------------------------------------------------------------------------------

[ljpc.jpg]

I acknowledge that, among other rights, I am waiving and releasing any rights I
may have under ADEA, that this Release and Waiver is knowing and voluntary, and
that the consideration given for this Release and Waiver is in addition to
anything of value to which I was already entitled as an executive of the
Company. If I am 40 years of age or older upon execution of this Release and
Waiver, I further acknowledge that I have been advised, as required by the Older
Workers Benefit Protection Act, that: (a) the release and waiver granted herein
does not relate to claims under the ADEA which may arise after this Release and
Waiver is executed; (b) I should consult with an attorney prior to executing
this Release and Waiver; (c) I have twenty-one (21) days in which to consider
this Release and Waiver (although I may choose voluntarily to execute this
Release and Waiver earlier); (d) I have seven (7) days following the execution
of this Release and Waiver to revoke my consent to this Release and Waiver; and
(e) this Release and Waiver shall not be effective until the eighth day after I
execute this Release and Waiver and the revocation period has expired (the
“Effective Date”).
I understand that among other things, I must not use or disclose any
confidential or proprietary information of the Company and I must immediately
return all Company property and documents (including all embodiments of
proprietary information) and all copies thereof in my possession or control.
This Release and Waiver constitutes the complete, final and exclusive embodiment
of the entire agreement between the Company and me with regard to the subject
matter hereof. I am not relying on any promise or representation by the Company
that is not expressly stated herein. This Release and Waiver may only be
modified by a writing signed by both me and a duly authorized officer of the
Company.  
 
 
 
 
 
 
 
Date:                                         
 
 
 
By:
 
 
 
 
 
Mink Chawla, M.D.